Table 3.
Top reactogenicity predictors (P ≤ 0.05) of increase in antibody titer*
| Reactogenicity predictors | β (log10 titer) | % change (increase) | % change (95% CI) | P |
|---|---|---|---|---|
| Severity per level with first dose | 0.226 | 68.1 | (4.6, 170.2) | 0.03 |
| Number of symptoms per symptom with second dose | 0.061 | 15.1 | (0.0, 32.4) | 0.05 |
| Site pain with first dose | 0.313 | 105.6 | (7.9, 291.8) | 0.03 |
| Fever with second dose | 0.309 | 103.6 | (3.1, 301.9) | 0.04 |
| Fatigue with second dose | 0.329 | 113.5 | (27.8, 256.8) | 0.004 |
*
Shown are the reactogenicity attributes and their associated changes in anti–SARS–CoV‐2 spike IgG+ antibody titers that, when present, predicted the largest increase in antibody titers compared to when attribute was not present; analysis was performed using tobit regression for each predictor, with adjustment for chronic inflammatory disease/healthy status, age, sex, and vaccine type. 95% CI = 95% confidence interval.